一种针对T细胞的Granzyme B-Cleavable双特异细胞囊连接器,用于逆转新发型1型糖尿病
Yanfang Wang1, Yanping Sun1, Xiuwen Zhang1
1State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Journal of the American Chemical Society
|January 27, 2025
概括
一种新的细胞囊疗法通过向CD8+T细胞,同时保持免疫功能来逆转新发型1型糖尿病 (T1D). 这种方法为T1D治疗提供了一个有希望的,更安全的替代方案,而不会增加感染风险.
科学领域:
- 免疫学
- 内分泌学
- 生物技术
背景情况:
- 1型糖尿病 (T1D) 是一种自身免疫性疾病,其特征是胰腺β细胞被CD8+ T细胞破坏.
- 目前的抗CD3抗体治疗在早期是有效的,但会导致暂时的免疫抑制,增加感染风险.
- 需要一种可以逆转疾病进展而不会损害免疫系统的T1D治疗方法.
研究的目的:
- 开发和评估一种基于细胞囊的新疗法 (aCD8-GrzBcs-IL2),用于逆转新发型1型糖尿病.
- 设计一种同时抑制致病性CD8+T细胞和促进调节性T细胞的疗法.
- 在临床前模型中评估新疗法的安全性和有效性.
主要方法:
- 具有抗CD8 scFv和IL-2突变蛋白的工程细胞囊.
- 在体外评估细胞囊泡抑制CD8+T细胞毒性和增强Treg细胞扩张的能力.
- 在患有新发糖尿病的非肥胖糖尿病小鼠中静脉注射aCD8- GrzBcs- IL2囊.
主要成果:
- 在体外研究表明,细胞囊抑制了CD8+T细胞的杀死,并促进了Treg细胞的扩张.
- 在77. 8%的NOD小鼠中,静脉注射aCD8-GrzBcs-IL2囊泡可以逆转新发型糖尿病.
- 治疗没有减少CD3+或CD8+T细胞总数,这表明安全性较好.
结论:
- 工程细胞囊泡 (aCD8-GrzBcs-IL2) 显示为一种双重作用的治疗方法.
- 在临床前的模型中,该疗法有效地逆转新发型糖尿病的免疫细胞群.
- 与现有疗法相比,这种方法代表了一种有前途的T1D治疗策略,具有更好的安全性.
相关概念视频
Cytotoxic T Cells-mediated Immune Response
835
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
835
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K


